CVS Group's (CVSG) "Hold" Rating Reiterated at Shore Capital Group

Key Points

• Shore Capital reiterated its “Hold” rating on CVS Group and maintained a GBX 1,400 price target, implying 14.19% potential upside from the prior close.
• Analyst sentiment remains positive overall, with four Buy ratings and two Holds producing a “Moderate Buy” consensus and an average price target of GBX 1,666.67.
• CVS Group shares opened at GBX 1,226, while insiders recently purchased shares; the company reported quarterly EPS of GBX 85.60 and operates more than 475 veterinary practices across the UK and Australia.

CVS Group (LON:CVSG - Get Free Report)'s stock had its "hold" rating reissued by analysts at Shore Capital Group in a research note issued to investors on Thursday, London Stock Exchange reports. They presently have a GBX 1,400 target price on the stock. Shore Capital Group's target price would suggest a potential upside of 14.19% from the stock's previous close.

Several other analysts have also recently commented on CVSG. Berenberg Bank reiterated a "buy" rating and set a GBX 2,000 price target on shares of CVS Group in a research report on Thursday. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating and issued a GBX 1,700 price objective on shares of CVS Group in a report on Monday, July 27th. Finally, Jefferies Financial Group increased their target price on shares of CVS Group from GBX 1,350 to GBX 1,400 and gave the stock a "hold" rating in a research note on Friday, July 31st. Four equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of GBX 1,666.67.

CVS Group Price Performance

Shares of CVS Group stock opened at GBX 1,226 on Thursday. The firm has a market cap of £833.31 million, a PE ratio of 17.79, a P/E/G ratio of 1.77 and a beta of 1.07. CVS Group has a twelve month low of GBX 1,062 and a twelve month high of GBX 1,648. The company has a quick ratio of 0.90, a current ratio of 1.07 and a debt-to-equity ratio of 92.34. The business has a 50-day moving average price of GBX 1,289.88 and a 200 day moving average price of GBX 1,230.

CVS Group (LON:CVSG - Get Free Report) last issued its quarterly earnings results on Thursday, September 24th. The company reported GBX 85.60 earnings per share (EPS) for the quarter. CVS Group had a return on equity of 5.35% and a net margin of 2.31%. Sell-side analysts predict that CVS Group will post 93.9393939 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider David Wilton purchased 1,500 shares of CVS Group stock in a transaction on Tuesday, August 4th. The shares were bought at an average price of GBX 1,276 per share, with a total value of £19,140. Also, insider Robin Alfonso bought 768 shares of CVS Group stock in a transaction that occurred on Thursday, August 6th. The stock was purchased at an average cost of GBX 1,294 per share, for a total transaction of £9,937.92. Insiders have purchased a total of 3,860 shares of company stock worth $4,956,696 in the last quarter. 1.48% of the stock is owned by company insiders.

About CVS Group

CVS Group is a leading provider of veterinary services, operating in the UK and Australia, listed on the Main Market of the London Stock Exchange. CVS is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy. The Group operates from over 475 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties) and an online retail business ("Animed Direct"). The Group employs c.8,900 personnel, including c.2,400 veterinary surgeons and c.3,300 nurses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.